Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

Aradigm Corporation today announced it is presenting data on September 22, 2010, from its Phase 1 studies at the ERS Annual Congress in Barcelona, Spain. The podium presentation elaborates on the pharmacokinetic parameters of ciprofloxacin in the blood and sputum samples that were observed in the healthy volunteers and non-cystic fibrosis bronchiectasis (BE) patients.

17 Sep 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

A new clinical trial supports the benefits to people with osteoarthritis who used a unique extract of turmeric. Scientists in Italy have studied the pain-relief, increased flexibility, and other effects of a special, patented extract of the roots of turmeric, the flavorful spice that has been used for centuries as a traditional remedy. Turmeric formulations have shown a wide range of safety and significant scientific and clinical benefits in recent animal research and human clinical trials.

16 Sep 2010

ESMO honors three eminent cancer specialists for their contribution towards medical research

The European Society for Medical Oncology (ESMO) honors three eminent cancer specialists for their contribution to the advancement of medical research. The awards will be presented to Hilary Calvert, Alberto Costa and Bengt Glimelius at the 35th ESMO Congress, to take place from 8-12 October in Milan, Italy.

16 Sep 2010

ESMO honors eminent cancer specialists

15 Sep 2010

COTI selected for Canadian life sciences partnering mission

Critical Outcome Technologies Inc. announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to attend a life sciences partnering mission in Boston, MA. This initiative is being held in conjunction with the BioPharm America conference taking place September 15-17, 2010.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Elsevier today announces that it has significantly increased its service offering to pharmaceutical R&D professionals with the launch of a new Pharmacokinetics Module of PharmaPendium-, the online resource for authoritative drug development data.

15 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

Genmab announces Phase II ofatumumab study results in RRMS patients

Genmab A/S announced today encouraging results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).

13 Sep 2010

FerroKin BioSciences initiates international Phase 2 study of FBS0701

FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.

10 Sep 2010

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA, being held September 12 -15 at the Boston Convention and Exhibition Center.

9 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.

8 Sep 2010

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

With its new expansion of the Pharmacogenomics Research Network (PGRN), the National Institutes of Health (NIH) awarded St. Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children.

8 Sep 2010

Pharmacokinetics News and Research

Further Reading

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

ESMO honors three eminent cancer specialists for their contribution towards medical research

ESMO honors eminent cancer specialists

COTI selected for Canadian life sciences partnering mission

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Genmab announces Phase II ofatumumab study results in RRMS patients

FerroKin BioSciences initiates international Phase 2 study of FBS0701

Tetraphase announces 13 data presentations on TP-434 broad spectrum antibiotic at ICAAC 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

NIH awards St. Jude $8.6M to focus on anticancer agent research in children

Industry Focus - Biopharma eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News